A phase II study of sequential velcade/thalidomide/dexamethasone as maintenance therapy post single autologous peripheral stem cell in patients with multiple myeloma

被引：0
|
作者：
Sahebi, F. [1 ]
机构：
[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA
来源：
BONE MARROW TRANSPLANTATION | 2010年 / 45卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S148 / S148
页数：1
相关论文
共 50 条
  • [41] Limite d b enefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea
    Byun, Ja Min
    Kim, Sang-A
    Koh, Youngil
    Shin, Dong-Yeop
    Kwon, Ji Hyun
    Kim, Jin Seok
    Kim, Kihyun
    Min, Chang-Ki
    Eom, Hyeon-Seok
    Lee, Je-Jung
    Bang, Soo-Mee
    Yoon, Sung-Soo
    CURRENT PROBLEMS IN CANCER, 2022, 46 (01)
  • [42] Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma
    Maiolino, Angelo
    Hungria, Vania T. M.
    Garnica, Marcia
    Oliveira-Duarte, Gislaine
    Oliveira, Luciana C. O.
    Mercante, Daniel R.
    Miranda, Eliana C.
    Quero, Adriana A.
    Peres, Ana L. M.
    Barros, Jose C.
    Tanaka, Paola
    Magalhaes, Roberto P.
    Rego, Eduardo M.
    Lorand-Metze, Irene
    Lima, Carmen S. P.
    Renault, Ilana Z.
    Braggio, Esteban
    Chiattone, Carlos
    Nucci, Marcio
    de Souza, Carmino A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (10) : 948 - 952
  • [43] Phase II study of thalidomide with dexamethasone for relapsed/refractory multiple myeloma
    Kinoshita, T
    Ohno, T
    Yuge, M
    Hiraga, J
    Matsushita, T
    Ando, S
    Naoe, T
    ANNALS OF ONCOLOGY, 2005, 16 : 206 - 206
  • [44] Autologous peripheral blood stem transplantation after thalidomide therapy of relapsed/refractory multiple myeloma patients
    Dmoszynska, A.
    Hus, M.
    Grzasko, N.
    Jawniak, D.
    Legiec, W.
    Wach, M.
    Cioch, M.
    Manko, J.
    Walter-Croneck, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S324 - S324
  • [45] CONTRIBUTION OF THALIDOMIDE MAINTENANCE TO LONG TERM RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
    Ozkurt, Z. N.
    Haznedar, R.
    Yegin, Z. A.
    Aki, S. Z.
    Ceneli, Oe
    Yagci, M.
    Sucak, G. T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 387 - 387
  • [46] High rate of complete remission and upgraded response with weekly maintenance bortezomib post single autologous peripheral stem cell transplant in patients with multiple myeloma. Results of a phase II prospective study
    Sahebi, F.
    Krishnan, A.
    Farol, L.
    Cai, J. -L.
    Somlo, G.
    Popplewell, L.
    Parker, P.
    Spielberger, R.
    Kogut, N.
    Karanes, C.
    Ruel, C.
    Frankel, P.
    Reburiano, E.
    Duarte, L.
    O'Donnell, L.
    Forman, S.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S39 - S39
  • [47] Bortezomib(Velcade®)-thalidomide-dexamethasone versus thalidomide-dexamethasone to treat multiple myeloma patients progressing or relapsing after autologous transplantation: the MMVAR trial
    Garderet, L.
    Iacobelli, S.
    Moreau, P.
    Onida, F.
    Koenecke, C.
    Scheid, C.
    Doyen, C.
    Bouko, Y.
    Ketterer, N.
    Masszi, T.
    Crawley, C.
    Hajek, R.
    Linkesch, W.
    Ludwig, H.
    Harousseau, J. L.
    Michallet, M.
    de Witte, T.
    Niederwieser, D.
    Gahrton, G.
    Morris, T. C. M.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S33 - S33
  • [48] Bortezomib (VELCADE®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:: Preliminary results of an IFM phase II study.
    Harousseau, JL
    Attal, M
    Leleu, X
    Gressin, R
    Hulin, C
    Fuzibet, JG
    Troncy, J
    BLOOD, 2004, 104 (11) : 416A - 416A
  • [49] Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients
    Martino, Massimo
    Console, Giuseppe
    Callea, Vincenzo
    Stelitano, Caterina
    Massara, Elisabetta
    Irrera, Giuseppe
    Messina, Giuseppe
    Morabito, Fortunato
    Iacopino, Pasquale
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 78 (01) : 35 - 40
  • [50] Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial
    Yoon, Suno-Soo
    Kim, Hye Jin
    Chung, Joo Seop
    Eom, HyeonSeok
    Jang, Jun-Ho
    Kang, Hye Jin
    Kim, Cheol Soo
    Kim, Kihyun
    Lee, Dongsoon
    Lee, Jae Hoon
    Lee, Junglim
    Lee, Sang Jae
    Min, Yoo Hong
    Seong, Chu-Myong
    Sohn, Sang-Kyun
    Suh, Cheolwon
    Won, Jong-Ho
    BLOOD, 2008, 112 (11) : 1144 - 1144
12345